Treatment of neovascular age-related macular degeneration: Past, present and future directions

Current Opinion in Ophthalmology

Volumn 18, Issue 3, 2007, Pages 240-244

  Smith, Bradley T ^a,b   Joseph, Daniel P ^a   Grand, M Gilbert ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b BARNES RETINA INSTITUTE   (United States)

Author keywords

Avastin; Choroidal neovascularization; Lucentis; Macular degeneration; Optical coherence tomography; Vascular endothelial growth factor

Indexed keywords

AG 013958; ANECORTAVE; BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; BEVASIRANIB; IMATINIB; PEGAPTANIB; RANIBIZUMAB; SIRNA 027; TRIAMCINOLONE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VATALANIB;

ABSENCE OF SIDE EFFECTS; ANTIANGIOGENIC ACTIVITY; ARGON PLASMA COAGULATION; ENDOPHTHALMITIS; FLUORESCENCE ANGIOGRAPHY; HUMAN; KRYPTON LASER; LASER COAGULATION; LENS DISEASE; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; THERAPY EFFECT; TREATMENT RESPONSE; VISUAL ACUITY;

CHOROIDAL NEOVASCULARIZATION; FORECASTING; HUMANS; MACULAR DEGENERATION; OPHTHALMOLOGIC SURGICAL PROCEDURES; TECHNOLOGY, PHARMACEUTICAL; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 34247211200     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32810c8e05     Document Type: Review

References (26)

1. Age-related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 2003; 121:1621-1624.
2. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122:564-572.
3. Thylefors B. A global initiative for the elimination of avoidable blindness. Am J Ophthalmol 1998; 125:90-93.
4. Seddon JM, Willett WC, Speizer FE, et al. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 1996; 276:1141-1146.
5. Seddon JM, Cote J, Rosner B. Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake. Arch Ophthalmol 2003; 121:1728-1737.
6. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119:1417-1436.
7. Salinas-Alaman A, Garcia-Layana A, Maldonado MJ, et al. Using optical coherence tomography to monitor photodynamic therapy in age related macular degeneration. Am J Ophthalmol 2005; 140:23-28.
8. Lalwani G, Fung AE, Michels S, et al. Optical coherence tomography findings in a variable-dosing regimen with ranibizumab (Lucentis™): the PrONTO Study [abstract]. In: ARVO Annual Meeting; 1 May 2006; Fort Lauderdale. Rockville: Association for Research in Vision and Ophthalmology; 2006. Abstract 2147/B726.
9. Macular Photocoagulation Study Group: Argon laser photocoagulation for neovascular maculopathy after 5 years: results from randomized clinical trials. Arch Ophthalmol 1991; 109:1109-1114.
10. Macular Photocoagulation Study Group. Laser photocoagulation of juxtafoveal choroidal neovascularization: 5-year results from randomized clinical trials. Arch Ophthalmol 1994; 111:500-509.
11. Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Arch Ophthalmol 1990; 108:825-833.
12. Macular Photocoagulation Study Group. Persistent and recurrent choroidal neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. Arch Ophthalmol 1994; 112:489-499.
13. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 1991; 109:1220-1231.
14. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two year results of 2 randomized clinical trials: TAP report no. 2. Arch Ophthalmol 2001; 119:198-207.
15. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005; 112:301-304.
16. Mordenti J, Cuthbertson RA, Ferrara B, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 1251-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999; 27:536-544.
17. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419-1431. This is the initial report of the safety and efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration.
18. Brown DM, Kaiser PK, Michels M, Soubrane G, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432-1444. This is a head to head trial of ranibizumab against photodymanic therapy, which is the only other FDA-approved treatment for neovascular age-related macular degeneration.
19. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006; 113:2002.
20. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36:331-335.
21. Preferences and Trends (PAT) Survey. In: American Society of Retina Specialists. Cannes, September 2006. http://www.asrs.org/. [Accessed 25 February 2006]
22. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al., VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351:2805-2816.
23. Brown D. PIER Study Presentation [Retinal Physician Website] July 2006. http://www.healthcareconferencegroup.com/conferences/63/pier.htm. [Accessed 7 January 2006]
24. Slakter JS, Bochow TW, D'Amico DJ, et al., Anecortave Acetate Clinical Study Group. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2006; 113:3-13.
25. Dhalla MS, Shah GK, Blinder KJ, et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006; 26:988-993.
26. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol 2006; 142:660-668. This is a nice overview of current antivascular endothelial growth factor agents complete with background of their development. It also includes details regarding the molecular structures and specific mechanisms of action.